MNNGF (Baijin Life Science Holdings) EBIT: $0.16 Mil (TTM As of Sep. 2025)


MNNGF Baijin Life Science Holdings Ltd MNNGF
35 GF Score
Price $0.08
GF Value $0.04
! 6 Warning Signs
View Full Analysis

What is Baijin Life Science Holdings EBIT?

Baijin Life Science Holdings MNNGF 35 EBIT is $0.16 Mil as of Sep. 2025. GuruFocus rates MNNGF with a GF Score™ of 35/100 and a GF Value™ of $0.04. The stock has 6 warning signs investors should review.

Baijin Life Science Holdings's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2025 was $0.39 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2025 was $0.16 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Baijin Life Science Holdings's annualized ROC % for the quarter that ended in Sep. 2025 was -11.04%. Baijin Life Science Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 7.11%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Baijin Life Science Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 0.10%.


Baijin Life Science Holdings  (OTCPK:MNNGF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Baijin Life Science Holdings's annualized ROC % for the quarter that ended in Sep. 2025 is calculated as:

ROC % (Q: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Sep. 2025 ))/ count )
=-2.988 * ( 1 - 0% )/( (28.355 + 25.751)/ 2 )
=-2.988/27.053
=-11.04 %

where

Note: The Operating Income data used here is two times the semi-annual (Sep. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Baijin Life Science Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Sep. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.778/( ( (2.167 + max(8.188, 0)) + (3.285 + max(8.24, 0)) )/ 2 )
=0.778/( ( 10.355 + 11.525 )/ 2 )
=0.778/10.94
=7.11 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.228 + 9.088 + 0) - (2.831 + 0 + 1.297)
=8.188

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.467 + 8.991 + 1.426) - (3.051 + 0 + 1.593)
=8.24

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Baijin Life Science Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2025 )
=0.157/165.080
=0.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baijin Life Science Holdings EBIT Related Terms


Baijin Life Science Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Baijin Life Science Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Baijin Life Science Holdings EBIT Chart

Baijin Life Science Holdings Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.13 -1.42 1.24 -1.06 -0.05

Baijin Life Science Holdings Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.28 -0.77 0.18 -0.23 0.39

MNNGF vs TPR: EBIT Comparison

For the Luxury Goods subindustry, Baijin Life Science Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baijin Life Science Holdings EV-to-EBIT vs Retail - Cyclical Industry

For the Retail - Cyclical industry and Consumer Cyclical sector, Baijin Life Science Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Baijin Life Science Holdings's EV-to-EBIT falls into.


MNNGF
35GF Score
Baijin Life Science Holdings Ltd MNNGF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Baijin Life Science Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $0.16 Mil mean?
Baijin Life Science Holdings (MNNGF) has a EBIT of $0.16 Mil as of Sep. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Baijin Life Science Holdings.
Is Baijin Life Science Holdings' EBIT too high?
Baijin Life Science Holdings' current EBIT is $0.16 Mil. Overall, Baijin Life Science Holdings has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Baijin Life Science Holdings' EBIT compare to TPR?
Baijin Life Science Holdings' EBIT of $0.16 Mil can be compared against companies in the Retail - Cyclical industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Retail - Cyclical company?
A good EBIT depends on the Retail - Cyclical industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Baijin Life Science Holdings. Baijin Life Science Holdings's current EBIT is $0.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baijin Life Science Holdings stock overvalued right now?
Baijin Life Science Holdings (MNNGF) has a current EBIT of $0.16 Mil. The stock's GF Value™ is $0.04, compared to a current price of $0.08 — trading 87.5% above its estimated fair value. The current EBIT is $0.16 Mil. Baijin Life Science Holdings' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Baijin Life Science Holdings (MNNGF), the current EBIT is $0.16 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Baijin Life Science Holdings (MNNGF) Overvalued in 2026?

Based on GuruFocus' analysis, Baijin Life Science Holdings stock appears to be overvalued. The current stock price of $0.08 is trading 87.5% above its estimated GF Value™ of $0.04.

Key valuation signals for MNNGF:

  • EBIT: $0.16 Mil
  • GF Value™: $0.04 vs. price of $0.08 (87.5% above fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the MNNGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Baijin Life Science Holdings Business Description

Other Exchanges 01466:Hong Kong
Address 66 Gloucester Road, Office B, 9/F Pico Tower, Wanchai, Hong Kong, HKG
Baijin Life Science Holdings Ltd is positioned as a biopharmaceutical company dedicated in anti-aging and preventive medicine, as well as cellular precision therapy. The company has three business segment: jewelry business segment; strategic investment segment; and skincare business segment. The majority of revenue is coming from jewelry business segment.
35GF Score

Get the complete analysis for MNNGF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price
$0.04
GF Value